Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor i kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

Investigational New Drugs

Volumn 33, Issue 2, 2015, Pages 357-370

  Rodón, Jordi ^a,g   Carducci, Michael ^b   Sepulveda Sánchez, Juan M ^c   Azaro, Analía ^a   Calvo, Emiliano ^a,h   Seoane, Joan ^a   Braña, Irene ^a   Sicart, Elisabet ^a   Gueorguieva, Ivelina ^d   Cleverly, Ann ^d   Pillay, N Sokalingum ^d   Desaiah, Durisala ^d   Estrem, Shawn T ^d   Paz Ares, Luis ^e   Holdhoff, Matthias ^b   Blakeley, Jaishri ^f   Lahn, Michael M ^d   Baselga, Jose ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d ELI LILLY AND COMPANY   (United States)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^h START   (Spain)

Author keywords

First in Human Dose; Galunisertib; Glioma; Pharmacodynamics; Pharmacokinetics; TGF inhibitor

Indexed keywords

ADAM PROTEIN; ADAM11 PROTEIN, HUMAN; ANTICONVULSIVE AGENT; LOMUSTINE; LY-2157299; MACROPHAGE DERIVED CHEMOKINE; PROTEIN SERINE THREONINE KINASE; PROTON PUMP INHIBITOR; PYRAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; SMAD2 PROTEIN; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; AREA UNDER THE CURVE; BIOSYNTHESIS; BLOOD CELL COUNT; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG INTERACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; NEOPLASMS; PHASE 1 CLINICAL TRIAL;

ADAM PROTEINS; ADULT; AGED; ANTICONVULSANTS; AREA UNDER CURVE; BLOOD CELL COUNT; CHEMOKINE CCL22; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LOMUSTINE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTON PUMP INHIBITORS; PYRAZOLES; QUINOLINES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SMAD2 PROTEIN; TUMOR SUPPRESSOR PROTEINS;

EID: 84939789948     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0192-4     Document Type: Article

References (32)

1. Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB (1981) New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci U S A 78:5339-5343
2. Massague J, Blain SW, Lo RS (2000) TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103:295-309
3. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R et al (2004) SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64:7954-7961
4. Anido J, Saez-Borderias A, Gonzalez-Junca A, Rodon L, Folch G, Carmona MA et al (2010) TGF-beta receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 18:655-668
5. Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, Mahapatra AK, Suri A et al (2011) Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neurol Oncol 13:132-142
6. Sawyer JS, Anderson BD, Beight DW, Campbell RM, Jones ML, Herron DK et al (2003) Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. J Med Chem 46:3953-3956
7. Gueorguieva I, Cleverly AL, Stauber A, Pillay NS, Rodon JA, Miles CP et al (2014) Defining a therapeutic window for the novel TGF-β inhibitor GALUNISERTIB monohydrate based on a pharmacokinetic/pharmacodynamic model. Br J Clin Pharmacol 77:796-807
8. Rodon J, Carducci MA, Sepúlveda JM, Azaro A, Calvo E, Seoane J, et al. (2013) First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. Clin Cancer Res (In press 2014)
9. Farrington DL, Yingling JM, Fill JA, Yan L, Qian YW, Shou J et al (2007) Development and validation of a phosphorylated SMAD ex vivo stimulation assay. Biomarkers 12:313-330
10. Baselga J, Rothenberg ML, Tabernero J, Seoane J, Daly T, Cleverly A et al (2008) TGF-beta signalling-related markers in cancer patients with bone metastasis. Biomarkers 13:217-236
11. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
12. Pursche S, Schleyer E, von Bonin M, Ehninger G, Said SM, Prondzinsky R et al (2008) Influence of enzyme-inducing antiepileptic drugs on trough level of Imatinib in glioblastoma patients. Curr Clin Pharmacol 3:198-203
13. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J et al (2013) Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nature Biotechnol 31:1023-1031
14. Brennan C (2011) Genomic profiles of glioma. Curr Neurol Neurosci Rep 11:291-297
15. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-1812
16. Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brustle A et al (2012) IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488:656-659
17. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110
18. Classen S, Muth C, Debey-Pascher S, Eggle D, Beyer M, Mallmann MR et al (2010) Application of T cell-based transcriptomics to identify three candidate biomarkers for monitoring anti-TGFbetaR therapy. Pharmacogenet Genomics 20:147-156
19. Tran DQ (2012) TGF-beta: the sword, the wand, and the shield of FOXP3(+) regulatory T cells. J Mol Cell Biol 4:29-37
20. Nancey S, Boschetti G, Cotte E, Ruel K, Almeras T, Chauvenet M et al (2012) Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab is associated with a profound long-lasting depletion of Foxp3+ regulatory T cells: a mechanistic explanation for ipilimumab-induced severe enterocolitis? Inflamm Bowel Dis 18:E1598-E1600
21. Crane CA, Ahn BJ, Han SJ, Parsa AT (2012) Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neurol Oncol 14:584-595
22. Sonabend AM, Rolle CE, Lesniak MS (2008) The role of regulatory T cells in malignant glioma. Anticancer Res 28:1143-1150
23. Baumann F, Leukel P, Doerfelt A, Beier CP, Dettmer K, Oefner PJ et al (2009) Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2. Neurol Oncol 11:368-380
24. Sreekanthreddy P, Srinivasan H, Kumar DM, Nijaguna MB, Sridevi S, Vrinda M et al (2010) Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev 19:1409-1422
25. Koorts AM, Levay PF, Becker PJ, Viljoen M (2011) Pro- and anti-inflammatory cytokines during immune stimulation: modulation of iron status and red blood cell profile. Mediat Inflamm 2011:716301
26. Brat DJ, Bellail AC, Van Meir EG (2005) The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neurol Oncol 7:122-133
27. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS et al (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6:327-338
28. Bruna A, Darken RS, Rojo F, Ocana A, Penuelas S, Arias A et al (2007) High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11:147-160
29. Kuczynski EA, Patten SG, Coomber BL (2011) VEGFR2 expression and TGF-beta signaling in initial and recurrent high-grade human glioma. Oncology 81:126-134
30. van den Boom J, Wolter M, Kuick R, Misek DE, Youkilis AS, Wechsler DS et al (2003) Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol 163:1033-1043
31. Flechsig P, Dadrich M, Bickelhaupt S, Jenne J, Hauser K, Timke C et al (2012) LY2109761 attenuates radiation-induced pulmonary murine fibrosis via reversal of TGF-beta and BMP-associated proinflammatory and proangiogenic signals. Clin Cancer Res 18:3616-3627
32. Zhang M, Herion TW, Timke C, Han N, Hauser K, Weber KJ et al (2011) Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-beta receptor I kinase inhibitor LY2109761. Neoplasia 13:537-549